Key Points
- Director Rick Winningham sold 2,741 shares of Jazz Pharmaceuticals on May 22 at an average price of $241.57, totaling about $662,143. The sale reduced his direct holdings by 22.27% to 9,567 shares.
- Jazz Pharmaceuticals stock was trading near its 52-week high, opening at $237.56 versus a 12-month high of $243.32 and low of $105.00. The company also has a market cap of about $14.9 billion.
- Analysts remain mostly positive on the stock, with a consensus rating of “Moderate Buy” and an average price target of $242.65. Recent calls included UBS raising its target to $307 and upgrading the stock to Buy.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) Director Heather Ann Mcsharry sold 2,000 shares of the business's stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the sale, the director owned 18,449 shares of the company's stock, valued at $4,446,209. This trade represents a 9.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Jazz Pharmaceuticals Price Performance
Shares of NASDAQ JAZZ opened at $237.56 on Thursday. The firm has a market cap of $14.90 billion, a PE ratio of -11,872.06, a PEG ratio of 0.42 and a beta of 0.27. The firm has a fifty day moving average of $205.91 and a 200 day moving average of $182.44. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. Jazz Pharmaceuticals PLC has a one year low of $105.00 and a one year high of $243.32.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. As a group, research analysts predict that Jazz Pharmaceuticals PLC will post 20.75 EPS for the current fiscal year.
Institutional Investors Weigh In On Jazz Pharmaceuticals
A number of large investors have recently modified their holdings of JAZZ. Royal Bank of Canada increased its stake in shares of Jazz Pharmaceuticals by 96.5% in the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company's stock worth $8,394,000 after acquiring an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Jazz Pharmaceuticals by 147.7% in the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company's stock valued at $43,652,000 after purchasing an additional 209,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Jazz Pharmaceuticals by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company's stock valued at $24,479,000 after purchasing an additional 7,954 shares during the period. Focus Partners Wealth grew its holdings in shares of Jazz Pharmaceuticals by 3.4% in the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company's stock valued at $574,000 after purchasing an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 137 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on JAZZ shares. Weiss Ratings raised shares of Jazz Pharmaceuticals from a "sell (d+)" rating to a "hold (c-)" rating in a report on Tuesday. Royal Bank Of Canada boosted their price target on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an "outperform" rating in a report on Wednesday, May 6th. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price objective for the company from $188.00 to $307.00 in a report on Tuesday, May 19th. Raymond James Financial restated an "outperform" rating and issued a $239.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Finally, TD Cowen upped their target price on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a "buy" rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $242.65.
View Our Latest Analysis on JAZZ
About Jazz Pharmaceuticals
(
Get Free Report)
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
